


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
ZYVOX, with the generic name Linezolid, is a synthetic antibacterial agent belonging to the oxazolidinone class. Its chemical name is (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide.
It is available in three formulations: intravenous injection, film-coated tablets, and an oral suspension for reconstitution. The drug operates by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, preventing the formation of the 70S initiation complex.
Nosocomial pneumonia
Community-acquired pneumonia, including concurrent bacteremia
Complicated skin and skin structure infections (e.g., diabetic foot infections without osteomyelitis)
Uncomplicated skin and skin structure infections
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia
Adults and adolescents (≥12 years): 600 mg IV or orally every 12 hours for most indications; 400 mg orally every 12 hours for uncomplicated skin infections.
Pediatric patients (birth to 11 years): 10 mg/kg every 8 hours IV or orally; for uncomplicated skin infections in children 5–11 years: 10 mg/kg every 12 hours orally.
Neonates (<7 days, preterm): 10 mg/kg every 12 hours, with possible adjustment to every 8 hours if clinically indicated.
Treatment duration ranges from 10 to 28 days depending on infection type and severity.
No dosage adjustment is required when switching from IV to oral administration.
